Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 22;120(6):612–620. doi: 10.1038/s41416-019-0389-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Cancer Research UK 2019

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

PMC Copyright notice

Fig. 3 — Schematic view of representative KIT secondary mutations after imatinib failure, frequency according to prior reports,^{8,9,11,18,36,37} and predicted activity profile of the three drugs currently approved for the treatment of GIST based on our studies. Green and red denotes sensitive and resistant, respectively, to imatinib (IM), sunitinib (SU) and regorafenib (RE). Regorafenib square for D816 is both red and green due to the presence of resistant amino acid changes (i.e., D816V is highly resistant to all TKIs)